Literature DB >> 12091372

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura.

Valentina Bianchi1, Rodolfo Robles, Lorenzo Alberio, Miha Furlan, Bernhard Lämmle.   

Abstract

A severe deficiency in von Willebrand factor-cleaving protease (ADAMTS13) activity (< 5% that in normal plasma) has been observed in most patients with a diagnosis of thrombotic thrombocytopenic purpura (TTP) but not in those with a diagnosis of hemolytic uremic syndrome. However, ADAMTS13 deficiency has been claimed not to be specific for TTP, since it was observed in various thrombocytopenic and other conditions. We studied 68 patients with thrombocytopenia due to severe sepsis or septic shock (n = 17), heparin-induced thrombocytopenia (n = 16), idiopathic thrombocytopenic purpura (n = 10), or other hematologic (n = 15) or miscellaneous conditions (n = 10). Twelve of the 68 patients had subnormal levels of ADAMTS13 activity (<or= 30%), but none had less than 10%. Thus, the study showed that ADAMTS13 activity is decreased in a substantial proportion of patients with thrombocytopenia of various causes. A severe deficiency of ADAMTS13 (< 5%), identified in more than 120 patients during 1996 to 2001 in our laboratory, is specific for a thrombotic microangiopathy commonly labeled TTP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12091372     DOI: 10.1182/blood-2002-02-0344

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  54 in total

1.  Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011.

Authors:  Sumit Som; Cassandra C Deford; Mandi L Kaiser; Deirdra R Terrell; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George; Sara K Vesely
Journal:  Transfusion       Date:  2012-04-15       Impact factor: 3.157

2.  Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome.

Authors:  Domenica Caramazza; Gerlando Quintini; Ignazio Abbene; Lucio Lo Coco; Alessandra Malato; Rosa Di Trapani; Giorgia Saccullo; Giuseppina Pizzo; Roberto Palazzolo; Rita Barone; Giuseppina Mazzola; Sergio Rizzo; Paolo Ragonese; Paolo Aridon; Vincenzo Abbadessa; Sergio Siragusa
Journal:  Blood Transfus       Date:  2010-07       Impact factor: 3.443

Review 3.  Current concepts in thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Annu Rev Med       Date:  2006       Impact factor: 13.739

Review 4.  Advantages and limits of ADAMTS13 testing in thrombotic thrombocytopenic purpura.

Authors:  Massimo Franchini; Pier Mannuccio Mannucci
Journal:  Blood Transfus       Date:  2008-07       Impact factor: 3.443

Review 5.  Thrombotic microangiopathy with targeted cancer agents.

Authors:  John A Blake-Haskins; Robert J Lechleider; Robert J Kreitman
Journal:  Clin Cancer Res       Date:  2011-08-03       Impact factor: 12.531

Review 6.  Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura.

Authors:  Minola Manea; Diana Karpman
Journal:  Pediatr Nephrol       Date:  2008-09-20       Impact factor: 3.714

7.  Enzymatically active ADAMTS13 variants are not inhibited by anti-ADAMTS13 autoantibodies: a novel therapeutic strategy?

Authors:  Wenhua Zhou; Lingli Dong; David Ginsburg; Eric E Bouhassira; Han-Mou Tsai
Journal:  J Biol Chem       Date:  2005-10-03       Impact factor: 5.157

8.  Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation.

Authors:  Yoshiaki Chinen; Junya Kuroda; Muneo Ohshiro; Yuji Shimura; Shinsuke Mizutani; Hisao Nagoshi; Nana Sasaki; Ryuko Nakayama; Miki Kiyota; Mio Yamamoto-Sugitani; Tsutomu Kobayashi; Yosuke Matsumoto; Shigeo Horiike; Masafumi Taniwaki
Journal:  Int J Hematol       Date:  2013-03-14       Impact factor: 2.490

Review 9.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

10.  Microangiopathic hemolytic anemia due to ADAMTS-13 loss in idiopathic systemic capillary leak syndrome.

Authors:  D C Moreira; C J Ng; R Quinones; X Liang; D W Chung; J Di Paola
Journal:  J Thromb Haemost       Date:  2016-10-24       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.